[{"id":"5140cf2b-ceba-4625-9ec1-ad9d0bbb9e1b","acronym":"KEYVIBE 007","url":"https://clinicaltrials.gov/study/NCT05226598","created_at":"2025-02-25T15:19:31.574Z","updated_at":"2025-02-25T15:19:31.574Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)","source_id_and_acronym":"NCT05226598 - KEYVIBE 007","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 739","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 09/24/2024","primary_completion_date":" 09/24/2024","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2025-02-11"},{"id":"38d14a85-f7dd-4762-9bf5-4da0e8be0e8f","acronym":"KEYMAKER-U04 Substudy","url":"https://clinicaltrials.gov/study/NCT05845814","created_at":"2023-05-06T15:04:43.804Z","updated_at":"2025-02-25T15:28:00.798Z","phase":"Phase 1/2","brief_title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","source_id_and_acronym":"NCT05845814 - KEYMAKER-U04 Substudy","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-10"},{"id":"69c870d6-f40e-4b1b-abc9-4c80e6cfc8ec","acronym":"KEYVIBE-006","url":"https://clinicaltrials.gov/study/NCT05298423","created_at":"2022-03-28T12:52:45.401Z","updated_at":"2024-07-02T16:34:25.855Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)","source_id_and_acronym":"NCT05298423 - KEYVIBE-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 784","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/04/2029","study_completion_date":" 09/04/2029","last_update_posted":"2024-06-14"},{"id":"c83f1ca5-f8ac-4ba6-b9aa-01738d1a4ab7","acronym":"KeyVibe-003","url":"https://clinicaltrials.gov/study/NCT04738487","created_at":"2021-02-04T18:58:44.596Z","updated_at":"2024-07-02T16:34:26.003Z","phase":"Phase 3","brief_title":"Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","source_id_and_acronym":"NCT04738487 - KeyVibe-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 1246","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/21/2026","primary_completion_date":" 04/21/2026","study_txt":" Completion: 06/05/2028","study_completion_date":" 06/05/2028","last_update_posted":"2024-06-14"},{"id":"9f8d313e-74c9-44df-85b7-d0e225eab089","acronym":"KEYSTEP-008","url":"https://clinicaltrials.gov/study/NCT04895722","created_at":"2021-05-20T11:54:07.770Z","updated_at":"2024-07-02T16:34:59.923Z","phase":"Phase 2","brief_title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","source_id_and_acronym":"NCT04895722 - KEYSTEP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/18/2025","study_completion_date":" 11/18/2025","last_update_posted":"2024-05-30"},{"id":"a64feebf-818b-47cf-b389-052e32de01bb","acronym":"KEYVIBE-001","url":"https://clinicaltrials.gov/study/NCT02964013","created_at":"2021-01-18T14:34:08.380Z","updated_at":"2024-07-02T16:35:08.757Z","phase":"Phase 1","brief_title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","source_id_and_acronym":"NCT02964013 - KEYVIBE-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 492","initiation":"Initiation: 12/13/2016","start_date":" 12/13/2016","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-18"},{"id":"f19510c6-4f6e-4c4a-acda-e326ec332711","acronym":"KEYVIBE-002","url":"https://clinicaltrials.gov/study/NCT04725188","created_at":"2021-01-26T15:52:24.286Z","updated_at":"2024-07-02T16:35:11.960Z","phase":"Phase 2","brief_title":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","source_id_and_acronym":"NCT04725188 - KEYVIBE-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 08/13/2027","study_completion_date":" 08/13/2027","last_update_posted":"2024-04-02"}]